Crispr Therapeutics shares tumble after significant earnings miss
In a turbulent market environment, GYRE stock has reached a new 52-week low, touching down at $8.26. According to InvestingPro analysis, the company maintains strong fundamentals with a current ratio of 3.32x, indicating robust liquidity. This latest price level reflects a significant downturn for the company, which has seen its stock value contract sharply over the past year. Investors have been closely monitoring GYRE’s performance, noting a stark 1-year change with the stock plummeting by nearly 47%. Despite the decline, GYRE maintains a healthy gross profit margin of 96% and appears undervalued according to InvestingPro Fair Value calculations. This decline has raised concerns among shareholders and market analysts alike, as they weigh the potential for recovery against ongoing market pressures and the company’s strategic responses to these challenges. InvestingPro subscribers can access 8 additional key insights about GYRE’s valuation and growth prospects, along with detailed financial health metrics that could signal potential recovery opportunities.
In other recent news, Gyre Therapeutics reported fourth quarter revenue of $27.87 million and provided full-year 2025 revenue guidance that did not meet analyst expectations. The company anticipates 2025 revenue between $118 million to $128 million, marking an 11.3% to 20.8% growth over 2024, yet falling short of the $135.7 million analysts had projected. Gyre’s 2025 outlook includes the commercial launches of nintedanib for idiopathic pulmonary fibrosis and avatrombopag for chronic liver disease-associated thrombocytopenia, with plans to introduce these in China alongside its existing ETUARY (pirfenidone) franchise. Additionally, Gyre Therapeutics has received approval from China’s National Medical (TASE:BLWV) Products Administration to initiate a clinical trial for pirfenidone, targeting radiation-induced lung injury and checkpoint inhibitor pneumonitis in cancer patients. The company plans to implement an adaptive Phase 2/3 trial design to evaluate pirfenidone’s efficacy in this new indication. Furthermore, Gyre has published the protocol for its Phase 3 trial on hydronidone for liver fibrosis in chronic hepatitis B patients, with topline results expected in the second quarter of 2025. The trial, conducted across 44 clinical research hospitals in China, aims to assess the drug’s impact on liver fibrosis reduction. Gyre’s parent company, Gyre Pharmaceuticals, reported 2024 net sales of $105.8 million for its flagship product, ETUARY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.